• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


OSB Lead-Australian Ortho Assc Natl Joint Registry

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Terminated
Application Number P040023 / PAS006
Date Current Protocol Accepted 04/20/2010
Study Name OSB Lead-Australian Ortho Assc Natl Joint Registry
General Study Protocol Parameters
Study Design Prospective & Retrospective Study
Data Source External Registry
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description Registry study
Sample Size In the 2009 AOA-NJRR Annual Report there were 666 hips reportedly implanted with a DURALOC Option Metal Outer Shell in combination with an S-ROM femoral stem.

DePuy does not yet have confirmation on the number of ceramic-on-ceramic articulations.

However, based on internal data it is anticipated that approximately 450 hips will have ceramic on ceramic articulations.

Data Collection DePuy will provide the following information as the data exists and is permitted by the AOA-NJRR:

¿ Femoral Stem types

¿ The years in which the surgeries were performed

¿ Patient demographic summaries (age, gender, diagnosis, height, weight, BMI)

¿ Patient listing of reasons for revisions

¿ Revision rate

¿ Death rate

Follow-up Visits and Length of Follow-up The length of follow-up for this study is 10 years. DePuy will request annual ad-hoc reports from the AOA-NJRR and provide these reports to the FDA in annual progress reports.

OSB Lead-Australian Ortho Assc Natl Joint Registry Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
1 year report 04/20/2011 04/21/2011 Overdue/Received
2 year report 07/03/2012 06/26/2012 On Time
3 year report 05/17/2013 05/30/2013 Overdue/Received

Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Related Links